FDA approved subcutaneous isatuximab-irfc for multiple myeloma. Phase 3 EMN24 trial showed 77% MRD negativity with Isa-KRd quadruplet therapy. Phase 2 study showed 77% hematologic response rate in relapsed/refractory AL amyloidosis.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07764978 |
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT |
RECRUITING | PHASE3 |
| NCT07709884 |
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen |
NOT_YET_RECRUITING | PHASE4 |
| NCT07247097 |
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT06348147 |
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation |
WITHDRAWN | PHASE2 |
| NCT05558319 |
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide |
RECRUITING | PHASE3 |
